

Product Name : meplazumab

Synonyms : —

Cat No. : M22102

CAS Number :

Molecular Formula : —

Formula Weight : —

Chemical Name : —

Description : meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. Compared to control group, meplazumab treatment significantly improved the discharged ($p=0.006$) and case severity ($p=0.021$) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; $p=0.014$, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation: Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile.

Pathway : Others

Target : Other Targets

Receptor : Others

Solubility : —

SMILES : —

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Huijie Bian, Zhao-Hui Zheng, Ding Wei, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. bioRxiv. 2020.